NCT01042236View on ClinicalTrials.gov

Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Stress Urinary Incontinence
Interventions
DRUG

Fesoterodine

Fesoterodine 4 mg and 8 mg and placebo - each dosed for 7 days with 7 day washout between dosing periods

Trial Locations (1)

2600

Glostrup Hospital, Glostrup Municipality

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY